Further studies on CD36 revealed that its overexpression in intra-tumor effector T cells exposes them to oxidative damage and ferroptosis due to lipid accumulation, and combining anti-PD-1 therapy with CD36 or ferroptosis inhibitors offered greater immunotherapeutic benefits (57). Here, CD36 is linked to neoplasm.